Northern Trust
TARS icon

Northern Trust’s Tarsus Pharmaceuticals TARS Stock Holding History

Northern Trust’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.3M Buy
386,611
+33,654
+10% +$2.15M ﹤0.01% 1682
2026
Q1 		$24.8M Buy
352,957
+10,471
+3% +$732K ﹤0.01% 1541
2025
Q4 		$28M Sell
342,486
-15,616
-4% -$1.17M ﹤0.01% 1451
2025
Q3 		$21.3M Buy
358,102
+924
+0.3% +$45.5K ﹤0.01% 1646
2025
Q2 		$14.5M Sell
357,178
-6,254
-2% -$281K ﹤0.01% 1848
2025
Q1 		$18.7M Buy
363,432
+5,816
+2% +$287K ﹤0.01% 1674
2024
Q4 		$19.8M Buy
357,616
+40,061
+13% +$1.82M ﹤0.01% 1692
2024
Q3 		$10.4M Buy
317,555
+64,539
+26% +$1.81M ﹤0.01% 2043
2024
Q2 		$6.88M Buy
253,016
+5,839
+2% +$196K ﹤0.01% 2219
2024
Q1 		$8.98M Sell
247,177
-1,573
-0.6% -$46.3K ﹤0.01% 2101
2023
Q4 		$5.04M Buy
248,750
+37,460
+18% +$626K ﹤0.01% 2506
2023
Q3 		$3.75M Buy
211,290
+18,007
+9% +$319K ﹤0.01% 2608
2023
Q2 		$3.49M Buy
193,283
+41,917
+28% +$666K ﹤0.01% 2699
2023
Q1 		$1.9M Sell
151,366
-3,149
-2% -$46.1K ﹤0.01% 2962
2022
Q4 		$2.27M Buy
154,515
+4,732
+3% +$78.3K ﹤0.01% 2941
2022
Q3 		$2.56M Buy
149,783
+10,636
+8% +$169K ﹤0.01% 2881
2022
Q2 		$2.03M Buy
139,147
+70,415
+102% +$1.06M ﹤0.01% 3058
2022
Q1 		$1.16M Sell
68,732
-3,049
-4% -$56.6K ﹤0.01% 3359
2021
Q4 		$1.61M Sell
71,781
-2,230
-3% -$58K ﹤0.01% 3327
2021
Q3 		$1.59M Sell
74,011
-5,624
-7% -$139K ﹤0.01% 3386
2021
Q2 		$2.31M Buy
79,635
+12,600
+19% +$394K ﹤0.01% 3286
2021
Q1 		$2.16M Sell
67,035
-3,364
-5% -$124K ﹤0.01% 3200
2020
Q4 		$2.91M Buy
+70,399
New +$2.01M ﹤0.01% 2987

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust's TARS Position: Q2 2026 in Review

Northern Trust increased its Tarsus Pharmaceuticals (TARS) stake by 9.5% in Q2 2026, buying an estimated $2.15M and bringing the position to 386,611 shares worth $24.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1682.

Northern Trust first reported a position in TARS in Q4 2020 and has held it in 23 quarters since. The position peaked at $28M in Q4 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Northern Trust held 386,611 shares of Tarsus Pharmaceuticals worth $24.3M as of Q2 2026.
  • Northern Trust bought 33,654 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $2.15M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1682 holding.
  • Northern Trust first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Northern Trust's Tarsus Pharmaceuticals position peaked at $28M in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.